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Abstract 
During pregnancy, adaptations occur in the maternal brain and body to ensure optimal 
nutrition for both the mother and fetus. Over nutrition in the mother can lead to gestational 
diabetes mellitus (GDM). GDM in mothers is a significant risk factor for development of 
cardiovascular disease and pre-eclampsia (Carr et al.,2011).  
The protein modification O-linked N-acetylglucosamine (O-GlcNAc) is derived from 
glucose through the hexosamine biosynthetic pathway (HBP) and has been shown to increase 
in hyperglycemic conditions and plays a role in the etiology of many diseases, including T2DM 
(Hart et al., 2011). Research on the changes of O-GlcNAcylation during pregnancy and 
lactation is scarce.  
My study aimed to determine any changes in O-GlcNAc expressing cells during the 
physiological conditions of pregnancy and lactation in the rat brain. I hypothesised that there 
would be an increased number of O-GlcNAc expressing cells during pregnancy due to higher 
blood glucose levels, which would normalise or decrease during lactation compared to non-
pregnant rats. 
Female Sprague Dawley rats were divided into 3 groups (diestrus, 21 days pregnant 
and day 7 lactating), perfused with 4% paraformaldehyde, brains removed and coronally sliced 
for immunohistochemistry. Single-label chromogen staining for O-GlcNAc was carried out in 
the ventromedial hypothalamus (VMH), paraventricular nucleus (PVN), supraoptic nucleus 
(SON), periventricular nucleus (Pe) and the anteroventral periventricular nucleus (AVPV). 
Single-label immunofluorescence for O-GlcNAc was carried out in the arcuate nucleus (ARC). 
Sections were photographed and analysed using FIJI (Image J) to count the number of 
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O-GlcNAc expressing cells in each area. There was no statistical difference between the 
number of O-GlcNAc expressing cells in pregnant and lactating rats compared with non-
pregnant rats in the ARC, PVN, SON, VMH, Pe and AVPV. 
Double-label immunofluorescence for O-GlcNAc and DFosB, a marker of chronic 
activation, was also carried out in the PVN. The average number of DFosB expressing cells and 
O-GlcNAc expressing cells were counted, no difference was detected between the non-
pregnant, pregnant and lactating groups. Furthermore, the percentage of DFosB cells co-
expressing O-GlcNAc and the percentage O-GlcNAc cells co-expressing DFosB revealed no 
difference between the non-pregnant, pregnant and lactating groups. The results from our 
study suggests that in a normal rat pregnancy and subsequent lactation the expression of O-
GlcNAc does not differ from non-pregnant expression.  
 
  
   
 iv 
Acknowledgements 
Firstly, I would like to pay special regards to Dr Rachael Augustine for being incredibly 
supportive and providing me with invaluable feedback and knowledge. For always having an 
open door and willingness to answer every question and making my year enjoyable. Thank 
you for all your help in the lab when I only had one working arm and when I was not able to 
be in Dunedin.  
Thank you to Professor Colin Brown for allowing me to work in your lab and for your 
willingness to provide feedback and guidance in my work. 
A special thank you to Associate Professor Stephen Bunn for allowing me to have time off 
when I broke my clavicle and being incredibly supportive with rearranging deadlines and 
extending my time as an Honour’s student.  
Thanks to my advisor Professor Alison Heather and to the University of Otago Physiology 
Department and Centre for Neuroendocrinology for the funding this year.  
Thank you to Michael Perkinson for sharing your knowledge and time with me, without 
you google would have worked twice as hard! Thanks for being willing to help and trouble 
shoot 24/7 even on New Year’s Day.  
I would also like to recognise the Brown Lab for the assistance and feedback on all my 
presentations and the 400 level students for assistance in stress relief and ice cream trips. 
Lastly thank you to my family and friends for all the support throughout the year.  
  
   
 v 
Table of Contents 
Abstract ii 
Acknowledgements iv 
Table of Contents v 
List of Figures ix 
List of Tables xi 
Abbreviations xii 
Chapter 1 Introduction 2 
 Preface 2 
 Physiological adaptations in pregnancy and lactation 3 
 Non-pregnant metabolic homeostasis 3 
1.3.1 Body weight homeostasis 3 
1.3.2 Glucose homeostasis 4 
 Metabolic homeostasis during pregnancy 5 
1.4.1 Body weight homeostasis 5 
1.4.2 Glucose homeostasis 5 
1.4.3 High risk pregnancy 6 
   
 vi 
 Metabolic homeostasis during lactation 7 
 Hemodynamic adaptations 7 
 O-linked N-acetylglucosamine 8 
1.7.1 O-GlcNAc and phosphorylation 11 
1.7.2 O-GlcNAcylation and disease 12 
 Regions of interest 13 
1.8.1 Arcuate nucleus, paraventricular nucleus and ventromedial hypothalamus: Food 
intake  13 
1.8.2 Paraventricular nucleus: Hemodynamic homeostasis 15 
1.8.3 Supraoptic nucleus 15 
1.8.4 Periventricular nucleus and anteroventral periventricular nucleus 15 
 Aims and hypothesis 16 
Chapter 2 Methods 18 
 Ethics 18 
 Animals 18 
 Tissue retrieval 19 
 Immunohistochemistry 20 
2.4.1 Single label chromogen immunohistochemistry 21 
2.4.2 Single label chromogen immunohistochemistry cover slipping 23 
2.4.3 Single label fluorescent immunohistochemistry 23 
   
 vii 
2.4.4 Fluorescent immunohistochemistry cover slipping 24 
2.4.5 Double label fluorescent immunohistochemistry 24 
 Microscopy 26 
 O-GlcNAc expressing cells analysis 26 
 Statistical analysis 27 
Chapter 3 Results 30 
 O-GlcNAc expression analysis in the rat brain 30 
3.1.1 Ventromedial hypothalamus 30 
3.1.2 Paraventricular nucleus 30 
3.1.3 Supraoptic nucleus 31 
3.1.4 Periventricular nucleus 39 
3.1.5 Anteroventral periventricular nucleus 39 
3.1.6 Arcuate nucleus 44 
 Co-expression analysis of O-GlcNAc and DFosB in the PVN of the rat brain 46 
Chapter 4 Discussion 52 
 O-GlcNAc expression 52 
 Mechanism for O-GlcNAcylation homeostasis 54 
 OGT as a nutrient sensor 55 
 Insulin resistance and O-GlcNAcylation 56 
   
 viii 
 Chronic activation in O-GlcNAcylated cells 57 
 Limitations and future directions 58 
4.6.1 First limitation of this study 58 
4.6.2 Second limitation of this study 59 
4.6.3 Third limitation of this study 60 




   
 ix 
List of Figures 
Figure 1.1: Nutrient flux through the hexosamine biosynthetic pathway (HBP). 9 
Figure 1.2 Pathologies as a result of abnormal O-GlcNAcylation. 11 
Figure 1.3 NPY/AgRP and POMC neuron actions within the ARC and PVN. 14 
Figure 2.1 Schematic of chromogen staining with DAB for O-GlcNAc expressing cells. 22 
Figure 2.2: Schematic of immunofluorescence for O-GlcNAc and DFosB expressing cells. 25 
Figure 3.1 Single label DAB staining for O-GlcNAc in the VMH. 32 
Figure 3.2 O-GlcNAc expressing cells in the VMH. 33 
Figure 3.3 Single label DAB staining for O-GlcNAc in the PVN. 34 
Figure 3.4 O-GlcNAc expressing cells in the PVN. 35 
Figure 3.5 Single label DAB staining for O-GlcNAc in the SON. 36 
Figure 3.6 O-GlcNAc expressing cells in the SON. 37 
Figure 3.7 Single label DAB staining for O-GlcNAc in the Pe. 40 
Figure 3.8 O-GlcNAc expressing cells in the Pe. 41 
Figure 3.9 Single label DAB staining for O-GlcNAc in the AVPV. 42 
Figure 3.10 O-GlcNAc expressing cells in the AVPV. 43 
Figure 3.11 Single label fluorescent staining for O-GlcNAc in the ARC. 44 
Figure 3.12  O-GlcNAc expressing cells in the ARC. 45 
Figure 3.13 Double label fluorescent staining. 47 
Figure 3.14 Fluorescent O-GlcNAc and DFosB staining in the PVN. 48 
Figure 3.15 O-GlcNAc expressing cells in the PVN. 49 
Figure 3.16 DFosB expressing cells in the PVN. 49 
Figure 3.17 The percentage of DFosB cells co-expressing O-GlcNAc in the PVN. 50 
   
 x 
Figure 3.18 The percentage of O-GlcNAc cells co-expressing DFosB in the PVN. 50 
Figure 4.1 Maintenance of O-GlcNAcylation homeostasis. 54 
  
   
 xi 
List of Tables 
Table 2.1 Primary Antibodies 20 
Table 2.2 Secondary Antibodies 20 
Table 2.3 Detection Reagents 21 
 
   
 xii 
Abbreviations 
a-MSH Alpha- Melanocyte Stimulating Hormone 
aCAMKII Alpha-Ca2+ Calmodulin-dependent Protein Kinase II 
ABC Actin Biotin Complex 
AgRP Agouti Related Peptide 
AKT Phosphokinase B 
AMPK 5’ adenosine monophosphate-activated Protein Kinase 
ARC Arcuate Nucleus 
AVPV Anteroventral Periventricular Nucleus 
CRH Corticotrophin-releasing Hormone 
CSF Cerebral Spinal Fluid 
DAB 3,3- diaminobenzidine 
DHB Dopamine beta-hydroxylase 
GABA Gamma Aminobutyric Acid 
GDM Gestational Diabetes Mellitus 
GnRH Gonadotropin-Releasing Hormone 
HBP Hexosamine Biosynthetic Pathway 
HPG Hypothalamic-Pituitary-Gonadal 
IRS Insulin Receptor Substrate 
LEPRs Leptin Receptors 
MC4R Melanocortin 4 Receptor 
NaBH4 Sodium Borohydride 
NiDAB Nickle enhanced 3,3- diaminobenzidine 
   
 xiii 
NPY Neuropeptide Y 
O-GlcNAc O-linked N-Acetylglucosamine 
OGA O-GlcNAcase 
OGT O-GlcNAc Transferase 
PDK1 Phosphoinositide-dependent Protein Kinase I 
Pe Periventricular Nucleus 
PFA Paraformaldehyde 
POMC Proopiomelanocortin 
PTMs Post Translational Modifications 
PVN Paraventricular Nucleus 
qPCR Quantitative Polymerase Chain Reaction 
SEM Standard Error of the Mean 
SF-1 Steroidogenic Factor- 1 
SNA Sympathetic Nerve Activity 
SON Supraoptic Nucleus 
TBS Tris Buffered Saline Solution 
TIIDM Type 2 Diabetes Mellitus 
TRH Thyrotropin-releasing Hormone 
UDP-GlcNAc Uridine diphosphate N-acetylglucosamine 






  Introduction 
 2 
Chapter 1 Introduction 
 Preface 
During pregnancy, many adaptations occur peripherally in the maternal body and centrally in 
the maternal brain to prepare for fetal development, subsequent childbirth and lactation. In 
this introduction, I will discuss how the body maintains metabolic homeostasis followed by 
adaptations that occur during pregnancy to body weight and glucose homeostasis. This 
ensures the mother and fetus receive with adequate nutrients during pregnancy and 
subsequent lactation. Additionally, I will talk about the normal hemodynamic adaptations 
which occur during pregnancy.  
Furthermore, I will inform of the consequences of abnormal adaptations in pregnancy 
that can lead to the development of gestational diabetes mellitus (GDM) or pre-eclampsia. 
Moreover, I will introduce the glucose derived posttranslational modification O-linked N-
acetylglucosamine (O-GlcNAc), its function in both metabolic homeostasis and the 
hemodynamic response in the brain and how it is regulated. I will then outline the role O-
GlcNAc plays in the etiology of disease and how this may contribute to GDM and pre-
eclampsia in pregnancy. Lastly, I will briefly describe the functions of the different nuclei that 
were analysed in this study. 
To summarise I will provide the aim of this project and the hypothesised outcome.  
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 Physiological adaptations in pregnancy and lactation 
During pregnancy, many physiological adaptations take place in both the maternal brain and 
body in preparation for fetal development, subsequent childbirth and lactation (Grattan, 
2011). Within the body cardiovascular, respiratory and metabolic systems are all adapted to 
ensure a healthy balance of oxygen and nutrients for both the mother and fetus (Soma-Pillay 
et al., 2016). Peripherally physical changes occur such as the development of a placenta to 
support the fetus and weight gain to provide energy for both fetal development and milk 
production. Centrally in the brain, changes occur in the behavior of the mother to protect and 
care for the child after birth. Hormone secretion is altered to decrease the stress response 
and reduce fever response to infection. Changes in hormone secretion also facilitates lactation 
and deals with increased metabolic demand (Grattan, 2011). Abnormal changes in these 
adaptations can lead to complications for both the mother and child during pregnancy or after 
birth.  
 
 Non-pregnant metabolic homeostasis 
1.3.1 Body weight homeostasis 
Homeostasis is the maintenance of optimal conditions in response to internal or external 
stimuli (Modell et al., 2015). In normal circumstances body weight is closely regulated, where 
energy intake equals energy expenditure allowing for very little to no variance (Kalra et al., 
1999). This regulation is maintained by hormones which can be fast acting from the stomach 
and gut, or slower, longer acting from adipose tissue (Saper et al.,2002, Scarpace et al., 2000). 
The main sight of action for these hormones are in the brain, within the hypothalamus, where 
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neural pathways increase appetite and food intake (orexigenic) or decrease appetite and food 
intake (anorexigenic) (Kalra et al., 1999). 
Leptin, released from adipose tissue, is one of the integral hormones which act in the 
hypothalamus of the brain on anorexigenic pathways as a satiety signal (Friedman & Halaas, 
1998). Leptin is a slow acting, long-lasting signal that regulates adipose tissue levels. An 
increase in adipose tissue means more leptin is secreted proportionately. Consequently, 
weight gain occurs due to excessive inadequate energy expenditure which can further lead to 
obesity and other pathologies.  
 
1.3.2 Glucose homeostasis 
Glucose homeostasis is regulated by hormonal and neural regulation which ensures fasting 
blood glucose levels do not go out of physiological range (3.9 – 5.5 mmol/L) (American 
diabetes association). Chronic hyperglycemia (blood glucose levels above 5.5 mmol/L) can 
have long term complications such as coronary artery disease, peripheral vascular disease, 
retinopathy, and neuropathy (Mouri & Badireddy, 2019). Conversely, symptoms of 
hypoglycemia have a rapid onset causing headaches, dizziness and confusion which can lead 
to a loss of consciousness, coma and death (Kalra et al., 2013).  
Normal glucose homeostasis is modulated by glucocorticoids which influence 
pancreatic a and b cell function. Pancreatic a cells secrete glucagon, and b cells secrete 
insulin, both vital hormones for glucose homeostasis (Kuo et al., 2015). Insulin is released from 
the pancreas into the bloodstream in response to increased blood glucose, stimulating uptake 
of glucose into cells in the brain and peripheral tissues. Glucose can be stored or utilised 
through many metabolic pathways to provide energy for cellular function. Glucagon is 
released in response to decreased blood glucose and acts to increase glucose availability by 
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increasing glucose synthesis and release into the blood (Kuo et al., 2015).  However, 
chronically elevated glucose levels can lead to insulin resistance throughout the body and 
eventually cause type II diabetes mellitus (TIIDM). 
 
 Metabolic homeostasis during pregnancy 
1.4.1 Body weight homeostasis 
During a normal pregnancy, body weight homeostasis changes to create a positive energy 
balance. This results in weight gain and fat deposition in order to provide energy for both the 
mother and fetus, as well as store energy for lactation after childbirth (Ladyman et al., 2010). 
The positive energy balance is achieved when the maternal brain becomes temporarily 
resistant to leptin, diminishing the satiety response (Grattan et al., 2007). Without the 
response to leptin the body continues to accumulate adipose tissue via an increase in food 
intake, leading to an imbalance between energy intake and energy expenditure, causing 
weight gain.  
 
1.4.2 Glucose homeostasis 
During a normal pregnancy, adaptations also occur in the metabolism of glucose to ensure a 
constant supply of glucose to the developing fetus. Peripherally, the maternal body becomes 
insulin resistant allowing for an increase in blood glucose which is subsequently shunted to 
the developing fetus (Newbern & Freemark, 2011). Euglycemia is maintained by 
compensatory mechanisms of the pancreatic b cells and increased hepatic gluconeogenesis. 
Pancreatic b cell proliferation is increased, expanding the islet cell mass, resulting in elevated 
insulin secretion. More importantly, the threshold for glucose stimulated insulin production is 
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decreased. This results in significantly more insulin release, within the same plasma glucose 
concentrations, causing hyperinsulinemia (Sorenson & Brelje, 1997). Although the maternal 
body becomes insulin resistant, compensatory increases of insulin still allow for partial 
regulation of blood glucose.  
Interestingly, another adaptation during pregnancy is the development of insulin 
resistance centrally in the brain of the mother (Ladyman & Grattan, 2017). Insulin resistance 
is thought to occur to prevent overstimulation of insulin targets within the brain as peripheral 
insulin levels are increased. However, in research done by Shi et al (2019) insulin transport 
into the brain and cerebral spinal fluid (CSF) were both increased but this was counteracted 
by an increase in insulin degradation and resulted in no overall change in insulin levels in the 
brain during pregnancy. Therefore, rather than preventing overstimulation from increased 
insulin levels there may be a different reason for central insulin resistance.  
 
1.4.3 High risk pregnancy 
Obesity, overnutrition and excessive weight gain disrupts energy homeostasis which, during 
pregnancy can cause complications such as hyperglycemia, GDM and pre-eclampsia 
(Bhattacharya et al., 2007, Rossner & Ohlin, 1995, Stone et al., 1994). Furthermore, both over 
and under nutrition is shown to predispose offspring to hypertension, obesity, TIIDM 
(Bhattacharya et al.,2007, Whitaker, 2004, Levin, 2006, Barker, 1997) and other disease states. 
When the maternal body is unable to compensate for the insulin resistance during pregnancy, 
pathological hyperglycemia and GDM can occur. Development of GDM can be derived from 
multiple causes including, significant decreases in insulin secretion (Angueira et al., 2015), 
failure of pancreatic b cells to proliferate (Sorenson & Brelje, 1997) and irrepressible hepatic 
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gluconeogenesis due to insulin resistance (He et al., 2009). Insulin resistance and GDM have 
both been identified as risk factors for the development of pre-eclampsia (Carr et al 2011).  
 
 Metabolic homeostasis during lactation 
Substantial adaptations in metabolic homeostasis occur again in the mother after childbirth 
to meet the different metabolic demands of lactation. The period of lactation is energetically 
demanding on the mother, with total energy requirements being significantly higher than that 
of non-pregnant and pregnant equivalents (Widdoson, 1976, Butte et al., 2001). During 
lactation, energy expenditure becomes greater than energy intake leading to a net weight 
loss. The increase in energy expenditure is partially sourced by fat mobilisation from adipose 
stores deposited during pregnancy and is supplemented by an increase in food intake 
(Widdoson, 1976, Butte et al., 2001).   
In contrast to pregnancy, lactating rats have both decreased plasma insulin (Flint et al., 
1979) and decreased plasma glucose levels (Burnol et al., 1983). Any glucose entering the 
blood stream is quickly utilised as it can be condensed with galactose to form lactose (Berg et 
al., 2002). Lactose is then either released in breast milk or utilised as energy required for the 
production of breast milk. Decreased levels of blood glucose results in decreased insulin 
secretion and increased glucagon secretion in attempt to restore euglycemia.  
 
 Hemodynamic adaptations 
Regulation of the mean arterial pressure in the body is key to maintain the circulation of blood. 
During pregnancy the blood volume expands, and total peripheral resistance decreases to 
allow adequate blood flow to the fetus (Humphreys & Joels, 1977). The mean arterial pressure 
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is partially maintained by baroreceptors in the arteries. They respond quickly to changes in 
arterial blood pressure and ensure hypertension or hypotension do not occur.  
During pregnancy, there is an impairment in the baroreceptor reflex, lowering its 
response to arterial pressure changes and decreasing the mother’s ability to rapidly control 
blood pressure and the ability to hemorrhage (Humphreys & Joels, 1977, Humphreys & Joels, 
1974). This adaptation is not beneficial to the mother or the fetus and has been associated 
with other conditions such as hypertension, TIIDM and heart failure (Bristow et al., 1969, 
Frattola et al., 1997, Eckberg et al.,1971). Furthermore, the conditions associated with 
impaired baroreflex show an association with insulin resistance, suggesting a correlation 
between insulin resistance and the baroreflex (Daubert et al., 2007, Brooks et al 2010). In 
Daubert’s study it was shown that as insulin sensitivity declines so does the baroreflex and 
furthermore, treating the animals with an insulin sensitizing drug (rosiglizone) almost 
normalised both the insulin sensitivity and the baroreflex. Insulin resistance has been 
identified as a risk factor for pre-eclampsia (Carr et al., 2011). Pre-eclampsia is also 
characterised by a further decline of the baroreflex function suggesting changes in the insulin 
signaling pathway are a major contributor to a wide range of pathologies.  
 
 O-linked N-acetylglucosamine 
O-GlcNAc is essential to life (Hart et al., 2007), regulated by both glucose levels and nutrient 
flux through the HBP (Figure 1.1). 2-3% of all extracellular glucose is taken up into the 
hexosamine biosynthetic pathway (HBP) where, through nutrient flux, uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc) is derived (Yang & Qian, 2017) (Figure 1.1). UDP-GlcNAc is 
the donor substrate for the post-translational protein modification of serine and threonine 
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residues by O-GlcNAc. Occurring in the nucleoplasm, cytoplasm and mitochondria, O-GlcNAc 
targets thousands of proteins regulating many cellular signaling, metabolic and structural 
pathways (Hart et al., 2007, Hart et al., 2011). Addition of O-GlcNAc from UDP-GlcNAc onto 
serine and threonine residues is facilitated by O-GlcNAc transferase (OGT) and the removal by 
O-GlcNAcase (OGA) (Wells et al., 2001) (Figure 1.1).  
Glucose enters the cell via a glucose transporter. A small amount of glucose is used for the 
HBP pathway, where through nutrient flux, UDP-GlcNAc is produced. OGT catalyses the 
addition of O-GlcNAc to proteins and OGA catalyses the removal of O-GlcNAc from proteins. 
Protein ribbons adapted from CSHL protein data bank. Figure by Murrell C. L, 2020 
 
Figure 1.1: Nutrient flux through the hexosamine biosynthetic pathway (HBP).  
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Homeostasis of O-GlcNAcylation is important to maintain optimal cellular function 
under fluctuating nutrient availability and stress conditions (Bond & Hanover, 2013). The OGT 
and OGA enzymes are sole regulators for the homeostasis of O-GlcNAcylation (Yang & Qian, 
2017). OGT catalyses the addition of UDP-GlcNAc onto a serine or threonine residue on a 
protein where UDP-GlcNAc then becomes O-GlcNAc. OGA catalyses the removal of O-GlcNAc 
from a protein by hydrolysation. OGT is highly sensitive to any changes in UDP-GlcNAc as it 
contains a UDP-GlcNAc binding site (Wrabl & Grishin, 2001), which allows careful 
manipulation of protein O-GlcNAcylation in response to the HBP flux (Hardville & Hart, 2014). 
In normal physiological conditions O-GlcNAcylation targets transcription, translation, gene 
expression, metabolism, the cytoskeleton, proteins involved in development and many other 
signaling pathways (Yang & Qian, 2017, Hart et al., 2011) working to protect the cell in 
response to nutrient availability and cellular stress. O-GlcNAcylation of proteins increases with 
nutrient availability and stress and decreases with decreased nutrient availability. 
Inappropriate O-GlcNAcylation has shown to play a major role in the etiology of many diseases 
including TIIDM. (Hart et al., 2011, Ma & Hart, 2013, Zeidan & Hart, 2010) (Figure 1.2).  
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O-GlcNAc addition to proteins is facilitated by O-GlcNAc transferase and the removal by O-
GlcNAcase. Excess or lack of O-GlcNAcylation can lead to many pathologies. Protein ribbons 
adapted from CSHL protein data bank. Figure by Murrell C. L, 2020 
 
1.7.1 O-GlcNAc and phosphorylation 
Post translational modifications (PTMs) increase the diversity of a protein’s function by 
addition of a group onto an amino acid side chain or by cleavage of peptide bonds (Walsh, 
2006). PTMs such as O-GlcNAc increase the diversity of many proteins, similarly, other PTMs 
such as phosphorylation exist. Phosphorylation regulates almost all classes of neural proteins 
and is the most eminent mechanism for neural plasticity (Nestler & Greengard, 1999). An 
abundance of protein kinases regulates the addition of a phosphate group onto serine or 
threonine residues (Nestler & Greengard, 1999). O-GlcNAcylation and phosphorylation are 
very similar in function, regulating protein activity and they both bind to serine and threonine 
residues of proteins.  
Figure 1.2 Pathologies as a result of abnormal O-GlcNAcylation.  
 
O-GlcNAc 
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Extensive cross talk between the two modifications has been reviewed (Hart et 
al.,2011, Wang et al., 2008). The relationship between phosphorylation and O-GlcNAcylation 
is described in four different ways. Firstly, phosphorylation and O-GlcNAcylation can be 
competitive for the same site (Comer & Hart, 2001) or competitive for nearby residues (Dias 
et al., 2009). A competitive occupancy of both O-GlcNAc and O-phosphate has also been 
described on distant sites (Omary et al., 1998). Lastly a cooperative relationship is described 
on the insulin receptor substrate (IRS) where different phosphorylation and O-GlcNAc sites 
are modified simultaneously (Ball et al., 2006). Phosphorylation and O-GlcNAcylation have 
also been shown to interact on each other’s regulatory enzymes.  OGT can be phosphorylated, 
and 5' adenosine monophosphate-activated protein kinase (AMPK) can be O-GlcNAcylated. 
This relationship can alter the substrate selectivity of OGT and AMPK targets as well as change 
the activity of OGT or AMPK respectively (Bullen et al., 2014). 
 
1.7.2 O-GlcNAcylation and disease 
Over expression of OGT has been shown to cause insulin resistance by impeding the 
expression of insulin responsive genes, leading to a diabetic etiology (Yang et al.,2008). There 
is evidence to suggest O-GlcNAcylation of phosphokinase B (AKT) and the IRS occurs in both 
the insulin and leptin signaling pathways (Yang et al., 2008, Bond & Hanover, 2013, Ball et al., 
2006). O-GlcNAc is hypothesised to play a role in the regulation of these kinases and excessive 
O-GlcNAcylation of AKT or IRS in pregnancy could contribute to the etiology of insulin 
resistance, GDM and pre-eclampsia. 
 A reversible outcome after hyperO-GlcNAcylation is possible as insulin resistance and 
GDM resolve after birth, and into lactation when blood glucose levels are much lower 
(Widdoson, 1976). 
  Introduction 
 13 
Currently, literature on O-GlcNAcylation changes in the brain during pregnancy or 
lactation is very scarce. Some literature has identified changes in placental O-GlcNAcylation 
due to hyperglycaemia in pregnancy which leads to foetal and placental defects (Brown et al., 
2018, Lima et al., 2018, Zang et al., 2016). It is well known that O-GlcNAcylation perturbance 
can be a precursor to TIIDM, cardiovascular disease and cancer (Hart et al., 2011, Ma & Hart, 
2013, Zeidan & Hart, 2010) however, O-GlcNAcylation has not yet been studied in the brain 
during pregnancy or in relation to GDM or pre-eclampsia.  
 
 Regions of interest 
O-GlcNAcylation changes within the brain during pregnancy and lactation is a fairly new area 
of research. This study has a broad focus on the hypothalamic area where the regions have 
functional roles in metabolic homeostasis, hemodynamic adaptations, lactation and fertility. 
1.8.1 Arcuate nucleus, paraventricular nucleus and ventromedial hypothalamus: 
Food intake  
The arcuate nucleus (ARC) contains cell bodies that synthesise agouti-related peptide (AgRP) 
/neuropeptide Y (NPY) and proopiomelanocortin (POMC) neurons (Morris, 1989, O’Donohue 
& Dorsa, 1982). AgRP/NPY and POMC neurons project to multiple areas of the brain including 
to the paraventricular nucleus (PVN) and the ventromedial hypothalamus (VMH) to regulate 
food intake (Bai et al., 1985, Kiss et al., 1984, Sternson et al.,2005). 
NPY/AgRP neurons are orexigenic, signal to increase food intake and are inhibited by leptin in 
the ARC. POMC neurons are anorexigenic, signal to decrease food intake and can be activated 
by leptin in the ARC. (Cowley et al.,2001) (Figure 1.3)  
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In the PVN AgRP and a-melanocyte stimulating hormone (a-MSH) control insulin 
sensitivity by binding to the G-coupled receptor melanocortin 4 (MC4R). AgRP released from 
AgRP neurons in the PVN acts as an antagonist for MC4R, and a-MSH released from POMC 
neurons in the PVN acts as an agonist for MC4Rs (Cowley et al., 1999) (Figure 1.3).  
 
The ARC contains NPY/AgRP and POMC neurons which are activated or inhibited by leptin to 
control food intake. NPY/AgRP and POMC neurons project to the PVN. AgRP and a-MSH bind 
to the MC4 receptor to regulate insulin sensitivity. Figure by Murrell C.L, 2020 
 
In the VMH, steroidogenic factor 1 (SF-1) neurons express leptin receptors (LEPRs) and 
can be activated by leptin to mediate energy homeostasis (Dhillon et al., 2006). The VMH can 
also suppress food intake by exciting POMC neurons that project from the ARC (Sternson et 
al., 2005).  
 
Figure 1.3 NPY/AgRP and POMC neuron actions within the ARC and PVN. 
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1.8.2 Paraventricular nucleus: Hemodynamic homeostasis 
The baroreflex is partially controlled within the PVN. Atrial distension activates (Deng & 
Kaufman, 1995) and gamma aminobutyric acid (GABA) inhibits sympathoexcitatory neurons 
in the PVN (Martin et al., 1991). During pregnancy activation within the PVN is markedly 
decreased (Deng & Kaufman, 1995) however, sympathetic tone is increased, and this could be 
mediated by a decrease in GABA activity allowing the sympathetic nerve activity (SNA) to 
increase (Martin et al., 1991). 
 
1.8.3 Supraoptic nucleus 
The supraoptic nucleus (SON) contains magnocellular neurons which release neuropeptides, 
either oxytocin or vasopressin. Oxytocin’s primary roles are to stimulate milk let-down during 
lactation and uterine contractions during birth. Vasopressin’s main role is in water balance 
(Brown et al., 2013).  
 
1.8.4 Periventricular nucleus and anteroventral periventricular nucleus 
The periventricular nucleus (Pe) and anteroventral periventricular nucleus (AVPV) primarily 
contain kisspeptin neurons (also found in the ARC) (Gottsch et al., 2004). Kisspeptin neurons 
secrete the hormone kisspeptin most commonly known for stimulating gonadotropin 
releasing hormone (GnRH) neurons and gonadotrophins as part of the hypothalamic-pituitary-
gonadal (HPG) axis (de Roux et al., 2003, Seminara et al., 2003). More recently kisspeptin is 
suggested to also play a role in energy balance and metabolism, particularly in infertility seen 
in those with under or over nutrition. Smith et al (2006) showed that kisspeptin neurons in 
the ARC can be regulated by leptin and insulin.  
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 Aims and hypothesis 
In the present study I aimed to quantify the number of O-GlcNAc expressing cells during the 
physiological conditions of pregnancy and lactation in the rat brain. Secondly, I aimed to 
determine if O-GlcNAc expressing cells were also chronically activated in the PVN of the 
hypothalamus. I hypothesised that there would be an increased number of O-GlcNAc 
expressing cells during pregnancy due to higher blood glucose levels, which would normalise 
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Chapter 2 Methods 
 Ethics 
All experiments were approved and were performed in accordance with the University of 




The tissue for all immunohistochemistry was acquired by Dr Rachael Augustine (Brown Lab, 
University of Otago) in 2018. Female Sprague Dawley rats (N=21) were obtained from the 
University of Otago Animal Facility at 10 weeks of age. The animals were housed in group 
cages, at room temperature (22°C ± 1°C) on a 12 hours light 12 hours dark cycle. Animals were 
fed ad libitum with standard chow and water. 
Rats were monitored daily to determine their stage of the estrous cycle. Vaginal smears 
were taken using a moistened cotton tip and cells placed on a glass slide. The smears were 
stained using toluidine blue and viewed under a light microscope to examine cell cytology. 
Rats have a four-day estrous cycle with one day in each of the following proestrus, estrus, 
metestrus and diestrus. Rats in proestrus, have a higher ratio of nucleated round cells with a 
scarce number of leukocytes in their smears. Females on proestrus were put overnight in a 
cage with a male rat and the next morning the presence of sperm in the vaginal smear 
determined mating had occurred (day 0 pregnancy).  Non-pregnant rats were euthanised on 
diestrus, late pregnant rats were euthanised on day 21 of pregnancy and lactating rats were 
euthanised on day 7 of lactation. Lactating rats gave birth on day 21 or 22 of pregnancy and 
pup numbers were adjusted on day 2 of lactation to 10 pups per dam. 
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 Tissue retrieval 
Rats were euthanised by transcardial perfusion. Firstly rats were deeply anaesthetised with 
an intraperitoneal injection of pentobarbital (300 mg kg-1). For lactating rats, pups were 
removed immediately prior to induction of anaesthesia. Deep anaesthesia was confirmed 
when the hind limbs had complete loss of withdrawal reflexes. Subsequently a horizontal 
incision was made in the abdominal cavity just below the diaphragm. The diaphragm was then 
pierced and the ribs lifted to expose the heart. The perfusion needle was inserted into the left 
ventricle of the heart and a small incision was made in the right atrium. 50 ml of saline was 
pumped through the perfusion needle into the rat to remove the blood followed by 200 ml of 
4% paraformaldehyde (PFA) (4 g paraformaldehyde, 0.3 g monobasic sodium phosphate, 100 
ml distilled H2O, 1.23 g dibasic sodium phosphate) in a phosphate buffer (0.1 M, pH 7.6) for 
fixation. The brains were immediately removed and post-fixed in 4% PFA overnight. In the 
morning the brains were transferred to 30% sucrose solution in phosphate buffer (0.1 M, pH 
7.6) and stored at 4 °C until they were infiltrated with sucrose. Brains were subsequently 
frozen on dry ice and stored at -80 °C until sectioned.  
Coronal brain sections were cut through the brain using a sliding microtome at -21 °C 
(Lyca, SM2400, Germany) into 4 series of sections through three consecutive areas of the 
hypothalamus; the Pe/AVPV, the PVN/SON and the ARC/VMH (0.4 bregma to -3.60 bregma).  
The tissue was stored in cryoprotectant (9 g sodium chloride, 300 g sucrose, 10 g 
polyvinylpyrrolidone dissolved in 500 ml of 1 M phosphate buffer and added to 300 ml 
ethylene glycol; makes 1 L) at -20 °C in the freezer before immunostaining.  
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 Immunohistochemistry 
Single label chromogen staining for O-GlcNAc, single label fluorescent staining for O-GlcNAc 
and double-label fluorescent staining for O-GlcNAc and DFosB were performed using the 
primary and secondary antibodies listed in Table 2.1, Table 2.2 and the detection reagents 







Table 2.1 Primary Antibodies   
Antibody Dilution Company 
Mouse anti-O-GlcNAc 1: 5000 Abcam., MA, USA 
Rabbit anti-DFosB 1:5000 Cell Signaling Technologies., 
MA, USA 
Table 2.2 Secondary Antibodies 
Antibody Label Dilution Company 
Goat anti-mouse IgG Biotin 1:500 Vector Laboratories 
Inc., CA, USA 
Goat anti-rabbit 488 Fluorescent 1:500 Life Technologies 
Corporation., CA, USA 
Streptavidin 568 Fluorescent 1:200 Life Technologies 
Corporation., CA, USA 
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2.4.1 Single label chromogen immunohistochemistry 
One series of the Pe/AVPV, PVN/SON or VMH/ARC tissue was used per round of 
immunohistochemistry. The cryoprotectant that the tissue was stored in was washed off (each 
wash consisted of 3 x 10-minute washes) in 1x Tris buffered saline (TBS) diluted from 10 x TBS 
(pH 7.4; Tris HCl 66.1 g, Tris Base 9.7 g, NaCl 87 g). The tissue was incubated in an endogenous 
peroxidase quench (1x TBS, methanol and 30% H2O2) for 30 minutes to prevent non-specific 
binding of antibodies to any endogenous peroxidases such as red blood cells. The quench was 
followed by more washes in TBS. The tissue was further incubated for 20 minutes at room 
temperature in blocking solution (0.3% Triton X-100, 0.25% bovine serum albumin in TBS and 
5% normal goat serum (Sigma Life Science, St. Louis, Missouri, USA)). This process blocks non-
specific binding of the antibodies to the tissue or Fc receptors. Tissue was then transferred to 
primary antibody (mouse anti- O-GlcNAc; Table 2.1) diluted (1:5000) in blocking solution and 
incubated for 48 hours at 4°C on an orbital shaker. Tissue was washed in TBS before being 
transferred to secondary antibody, (biotinylated goat anti-mouse IgG; Table 2.2) diluted 
(1:500) in incubation solution (0.3% Triton X-100, 0.25% bovine serum albumin in TBS), for 90 
minutes at room temperature. Once incubated, the secondary antibody was removed by 
washing the tissue in TBS before being transferred to avidin biotin complex (ABC; Table 2.3), 
Detection Reagents Label Dilution Company 
Avidin Biotin Complex 
(ABC)  
Tertiary 1:100 Vector Laboratories 
Inc., CA, USA 
Nickel enhanced 3,3’ -
diaminobenzidine (NiDAB) 
Chromogen 1:50 Vector Laboratories 
Inc., CA, USA 
Table 2.3 Detection Reagents 
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diluted (1:100) in incubation solution, for 90 minutes at room temperature. The tissue was 
then washed in TBS. 
For chromogen labelling a standard nickel enhanced 3,3’ -diaminobenzidine (NiDAB) 
reaction was used. To make up NiDAB, 25 ml acetate buffer, (3.28 g sodium acetate and 200 
ml H2O) 1.25 g nickel sulphate, 0.2 g glucose and 0.04 g ammonium chloride was dissolved. 
Once dissolved 25 ml H2O was added with 1 ml DAB. Just before adding the tissue to the DAB 
solution 0.0015 g glucose oxidase was added to start the reaction. The target protein was 
visualised as NiDAB oxidised to a black precipitate; the reaction was stopped by washing the 
tissue in TBS.  
The protein expresses O-GlcNAc (yellow) which the primary antibody binds to (pink). The 
secondary antibody (orange) binds to the primary antibody and the signal is amplified by ABC 
complex (purple and green). NiDAB reacts with glucose oxidase to form a black precipitate. 
Figure by Murrell C. L, 2020. 
Figure 2.1 Schematic of chromogen staining with DAB for O-GlcNAc expressing cells. 
 
  Methods 
 23 
2.4.2 Single label chromogen immunohistochemistry cover slipping 
The brain slices were mounted onto gelatine-coated glass microscope slides, covered and left 
to dry overnight. Any water was removed from the tissue in a series of ethanol baths diluted 
with milliQ water starting with 50% ethanol for 3 min, 70% - 3 min, 90% - 3 min, 100% - 3 min, 
100% - 3 min. The slides were then transferred to xylene for 5 minutes and to a second xylene 
bath whilst waiting to be cover slipped. Slides were removed from the xylene and a couple of 
drops of distyrene plasticizer xylene (DPX, Merck KGaA, Darmstadt, Germany) was applied 
immediately. The coverslip was then carefully lowered onto the slide with any air bubbles 
dispersed to the edges of the slide. Slides were left overnight to dry before imaging.  
 
2.4.3 Single label fluorescent immunohistochemistry 
Fluorescent immunohistochemistry was used to detect O-GlcNAc in the arcuate nucleus. The 
indirect fluorescent method was used in the ARC as the DAB stain was too sensitive resulting 
in black background staining throughout the ARC including the no primary antibody control. 
The fluorescent antibody used is less sensitive (This can be seen in our results where the 
overall number of O-GlcNAc expressing cells in the PVN are much lower using the fluorescent 
method compared to the DAB stain (Figure 3.4, 3.15)) and therefore we may be able to detect 
cells with less background staining.  
Tissues were firstly washed in TBS to remove cryoprotectant. They were then 
incubated in 1% sodium borohydride (NaBH4) for 20 minutes to remove any aldehydes from 
fixation. The tissue was washed in TBS until all the bubbles had dissipated before incubation 
in blocking solution for 60 minutes at room temperature. The tissue incubated in primary 
antibody mouse anti-O-GlcNAc (1:5000) (Table 2.1) diluted in blocking solution for 48 hours 
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at 4°C on an orbital shaker. Primary antibody was removed by washing in TBS. The secondary 
antibody was carried out using the indirect method (biotinylated secondary antibody and 
streptavidin conjugated fluorophore). The tissue was firstly incubated in biotinylated goat 
anti-mouse IgG (Table 2.2) diluted (1:500) in incubation solution for 60 minutes. The sections 
were then washed in TBS and incubated in the secondary antibodies (streptavidin 568 (1:200) 
Table 2.2) diluted in incubation solution, for 3 hours in total darkness. Finally, the tissue was 
washed in TBS before mounting and cover slipping.  
 
2.4.4 Fluorescent immunohistochemistry cover slipping 
The brain slices were mounted onto gelatin- coated glass microscope slides, left to dry for a 
couple of hours avoiding exposure to light. Once dry the slides were dipped in milliQ water 
and promptly had a few drops of fluoromount G applied (SouthernBiotech, Birmingham, 
Alabama). The cover slip was slowly lowered onto the slide and any air bubbles were dispersed 
to the edges of the slide. Slides were left to dry in the dark and stored in the fridge at 4 °C.  
 
2.4.5 Double label fluorescent immunohistochemistry  
Fluorescent immunohistochemistry was used to detect both O-GlcNAc and DFosB in the PVN. 
Chromogen labelling would not work as O-GlcNAc and DFosB can be found in both the nucleus 
and cytoplasm. PVN brain slices were firstly washed in TBS to remove cryoprotectant. They 
were then incubated in 1% NaBH4 for 20 minutes to remove any aldehydes from fixation. The 
tissue was washed in TBS until all the bubbles had dissipated before incubation in blocking 
solution for 60 minutes at room temperature. A primary antibody cocktail of both mouse anti-
O-GlcNAc (1:5000) and rabbit anti-DFosB (1:5000) diluted in blocking solution was made. The 
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tissue was added and incubated for 48 hours at 4°C on an orbital shaker. The primary antibody 
was removed by washing in TBS. The secondary antibody was carried out using the direct 
method (fluorophore tagged secondary antibody) for DFosB and the indirect method 
(biotinylated secondary antibody and streptavidin conjugated fluorophore) for O-GlcNAc. All 
tissue underwent both methods for the double label immunostaining. Firstly, tissue was 
incubated for 60 minutes in biotinylated goat anti-mouse IgG (Table 2.3) diluted (1:500) in 
incubation solution. The sections were then washed in TBS and incubated in the secondary 
antibodies (streptavidin 568 (1:200) and goat anti-rabbit 488 (1:500); Table 2.2) diluted in 
incubation solution, for 3 hours in total darkness. Finally, the tissue was washed in TBS before 
mounting and cover slipping as described above (2.4.4). 
 
Figure 2.2: Schematic of immunofluorescence for O-GlcNAc and DFosB expressing cells. 
The protein expresses O-GlcNAc (yellow) and DFosB (purple) which the primary antibodies 
bind to (for O-GlcNAc pink, for DFosB blue). The secondary antibody for DFosB is fluorophore 
tagged and binds to the primary antibody. The secondary antibody for O-GlcNAc is biotinylated 
and binds to streptavidin which expresses the fluorophore. Figure by Murrell C.L, 2020 
  Methods 
 26 
 Microscopy 
The DAB stained slides were viewed using the Olympus BX61 (Olympus, Tokyo, Japan) light 
microscope with 10x and 20x objectives and photographed using Micropublisher 5.0 RTV 
digital camera (Teledyne Q imaging, Surrey, British Columbia, Canada). Images were obtained 
using Qcapture Suit PLUS software. 
The fluorescent stained slides were viewed using the Olympus BX51 (Olympus, Tokyo, 
Japan) epifluorescent microscope with 10x and 20x objectives and photographed using 
PROGRES GRYPHAX digital camera (Jenoptik, Jena, Germany). Images were obtained using 
PROGRES GRYPHAX software.  
 O-GlcNAc expressing cells analysis 
Analysis of the DAB stained images and fluorescent ARC images were completed using FIJI 
version 2.0 (Image J) software. Bilateral images of 3 representative sections were taken in each 
animal for each area (PVN, SON, VMH, ARC). The number of Pe and AVPV sections were limited 
so every section was imaged. Using FIJI’s pencil tool a border was drawn around the region of 
interest and using FIJI’s multipoint tool each stained cell was counted. During this process the 
analyser was blinded not knowing which group the animal belonged to. This was to ensure no 
bias counting occurred. A second blinded analyser counted a random assortment of sections 
to verify the number of positive counted cells. The average number of O-GlcNAc expressing 
cells was calculated from 3 bilateral sections per animal. These averages were then assorted 
into the respective groups non-pregnant, pregnant or lactating where a group average was 
then calculated. 
Analysis of the double label fluorescent images was completed using FIJI version 2.0 
(Image J) software. Bilateral images of 3 representative PVN sections per animal were taken. 
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The number of O-GlcNAc expressing cells (red) and DFosB expressing cells (green) were 
counted for 3 bilateral sections per animal. Images of the O-GlcNAc and DFosB staining were 
overlaid using FIJI and co-expressed cells were counted. The average number of O-
GlcNAc/DFosB expressing cells per animal was calculated. These were then assorted into non-
pregnant, pregnant and lactating groups were an average per group was calculated. The 
percentage of O-GlcNAc co-expressing DFosB and DFosB co-expressing O-GlcNAc was 
calculated using the average number of O-GlcNAc or DFosB expressing cells per animal. 
 
 Statistical analysis 
Statistical analysis was calculated by taking an average cell count from 3 bilateral sections for 
each animal and then an average cell count per group (pregnant, non-pregnant, and lactating). 
All data was expressed as a mean ± standard error of the mean (SEM). A one-way ANOVA was 
used for all experiments to determine any statistical difference in the number of positively stained 
cells in non-pregnant, pregnant and lactating groups.  
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Chapter 3 Results 
 O-GlcNAc expression analysis in the rat brain  
DAB immunohistochemistry was carried out to identify O-GlcNAc-expressing cells in the brains 
of non-pregnant, pregnant and lactating rats. Immunohistochemical staining showed dense 
O-GlcNAc expression throughout the rat brain. Analysis of O-GlcNAc expressing cells was 
carried out in multiple regions of interest throughout the rat brain.  
 
3.1.1 Ventromedial hypothalamus 
In the VMH the mean numbers of O-GlcNAc expressing cells were 499 ± 126 (SEM) in the non-
pregnant group (n = 8), 241 ± 72 in the pregnant group (n = 7) and 434 ± 174 positive cells in 
the lactating group (n = 5). In the VMH analysis revealed no statistical difference in the 
numbers of O-GlcNAc expressing cells between non-pregnant, pregnant and lactating rats (F 
(2, 17) = 1.32 p = 0.29, one-way ANOVA) (Figure 3.1, 3.2).  
 
3.1.2 Paraventricular nucleus 
In the PVN the mean number of cells were 700 ± 63 cells in the non-pregnant group (n = 8), 
671 ± 58 in the pregnant group (n = 7) and 626 ± 62 O-GlcNAc expressing cells in the lactating 
group (n = 6). There was no statistical difference in the numbers of O-GlcNAc expressing cells 
in the PVN between the non-pregnant, pregnant and lactating rats (F (2, 18) = 0.36 p = 0.70, one-
way ANOVA) (Figure 3.3, 3.4).  
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3.1.3 Supraoptic nucleus 
The mean numbers of O-GlcNAc expressing cells in the SON were 153 ± 12 in the non-pregnant 
(n = 8) group, 163 ± 20 in the pregnant group (n = 7) and 172 ± 17 positive cells in the lactating 
group (n = 6). Statistical analysis revealed no difference in the numbers of O-GlcNAc expressing 
cells in the SON between non-pregnant, pregnant and lactating rats (F (2, 18) = 0.36 p = 0.70, 
one-way ANOVA). (Figure 3.5, 3.6).   
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Non-pregnant            Pregnant 
O-GlcNAc expressing cells.          Lactating  
Representative images showing DAB stained O-GlcNAc expressing cells (black stain) in the 
ventromedial hypothalamus of non-pregnant, pregnant and lactating rats.  
Red dashed line = boundary of counted area. Scale bar = 200 µm. 
The insert from the non-pregnant rat image is an enlarged to view of O-GlcNAc staining 
showing more detail. Scale bar = 50 µm. 
 
  
Figure 3.1 Single label DAB staining for O-GlcNAc in the VMH. 
t
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Bar graph showing the mean (± SEM) number of O-GlcNAc expressing cells in non-pregnant, 
pregnant and lactating rats in the ventromedial hypothalamus. Within each bar the individual 
scatter plot represents the mean number of O-GlcNAc expressing cells for each animal in the 
group.  
One- way ANOVA revealed no statistical difference between the groups F (2,17) = 1.32, p = 0.29. 
  
Figure 3.2 O-GlcNAc expressing cells in the VMH. 
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    Lactating 
Representative images showing DAB stained O-GlcNAc expressing cells (black stain) in the 
paraventricular nucleus of non-pregnant, pregnant and lactating rats.  
Red dashed line = boundary of counted area. Scale bar = 100 µm. 
  
Figure 3.3 Single label DAB staining for O-GlcNAc in the PVN. 
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Bar graph showing the mean (± SEM) number of O-GlcNAc expressing cells in non-pregnant, 
pregnant and lactating rats in the paraventricular nucleus. Within each bar the individual 
scatter plot represents the mean number of O-GlcNAc expressing cells for each animal in the 
group.  
One-way ANOVA revealed no statistical difference between the groups F (2,18) = 0.36, p = 0.70. 
 
Figure 3.4 O-GlcNAc expressing cells in the PVN. 
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Non-pregnant            Pregnant 
    Lactating 
 
Representative images showing DAB stained O-GlcNAc expressing cells (black stain) in the 
supraoptic nucleus of non-pregnant, pregnant and lactating rats.  
OC = Optic chiasm. Red dashed line = boundary of counted area. Scale bar = 100 µm. 
  
Figure 3.5 Single label DAB staining for O-GlcNAc in the SON. 
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Bar graph showing the mean (± SEM) number of O-GlcNAc expressing cells in non-pregnant, 
pregnant and lactating rats in the supraoptic nucleus. Within each bar the individual scatter 
plot represents the mean number of O-GlcNAc expressing cells for each animal in the group. 
One-way ANOVA revealed no statistical difference between the groups F (2,18) = 0.36, p = 0.70. 
 
  
Figure 3.6 O-GlcNAc expressing cells in the SON. 




















Intentionally left blank  
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3.1.4 Periventricular nucleus 
In the Pe the mean numbers of O-GlcNAc expressing cells were 330 ± 73 in the non-pregnant 
group (n = 4), 245 ± 40 in the pregnant group (n = 2) and 412 ± 115 in the lactating group (n = 
2). There was no statistical difference in O-GlcNAc expressing cells between the non-pregnant, 
pregnant and lactating rats (F (2, 5) = 0.75, p = 0.52, one-way ANOVA) (Figure 3.7, 3.8).  
 
3.1.5 Anteroventral periventricular nucleus 
The mean number of O-GlcNAc expressing cells in the AVPV were 259 ± 36 in the non-pregnant 
group (n = 5), 197 ± 37 in the pregnant group (n = 7) and 153 ± 4 in the lactating group (n = 3). 
Analysis revealed no statistical difference in the number of O-GlcNAc expressing cells between 
non-pregnant, pregnant and lactating rats (F (2, 12) = 1.6, p = 0.24) (Figure 3.9, 3.10).  
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Non-Pregnant            Pregnant 
      Lactating 
Representative images showing DAB stained O-GlcNAc expressing cells (black stain) in the 
periventricular nucleus of non-pregnant, pregnant and lactating rats.  
OC = optic chiasm. 3V = third ventricle. 
Red dashed line = boundary of counted area. Scale bar = 200 µm. 
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Bar graph showing the mean (± SEM) number of O-GlcNAc expressing cells in non-pregnant, 
pregnant and lactating rats in the periventricular nucleus. Within each bar the individual 
scatter plot represents the mean number of O-GlcNAc expressing cells for each animal in the 
group.   
One-way ANOVA revealed no statistical difference between the groups F (2, 5) = 0.75, p = 0.52. 
  
Figure 3.8 O-GlcNAc expressing cells in the Pe. 
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Non-Pregnant            Pregnant 
      Lactating 
Representative images showing DAB stained O-GlcNAc expressing cells (black stain) in the 
anteroventral periventricular nucleus of non-pregnant, pregnant and lactating rats.  
OC = optic chiasm. 3V = third ventricle. 
Red dashed line = boundary of counted area. Scale bar = 200 µm. 
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Bar graph showing the mean (± SEM) Number of O-GlcNAc expressing cells in non-pregnant, 
pregnant and lactating rats in the anteroventral periventricular nucleus. Within each bar the 
individual scatter plot represents the mean number of O-GlcNAc expressing cells for each 
animal in the group.  
One-way ANOVA revealed no statistical difference between the groups F (2, 12) = 1.6, p = 0.24.   
Figure 3.10 O-GlcNAc expressing cells in the AVPV. 
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3.1.6 Arcuate nucleus 
Fluorescent immunohistochemistry was carried out to identify O-GlcNAc expressing cells in 
the ARC of non-pregnant, pregnant and lactating rats. The mean number of O-GlcNAc 
expressing cells were 124 ± 16 in the non-pregnant group (n = 8), 140 ± 17 in the pregnant 
group (n = 7) and 97 ± 12 in the lactating group (n = 6). Analysis revealed no statistical 
difference in the numbers of O-GlcNAc expressing cells in the ARC between non-pregnant, 
pregnant and lactating rats (F (2, 18) = 1.75, p = 0.20, one-way ANOVA) (Figure 3.11, 3.12). 
Non-pregnant     Pregnant 
      Lactating 
Representative images showing fluorescent stained O-GlcNAc expressing cells (red stain) in 
the arcuate nucleus of non-pregnant, pregnant and lactating rats.  
White dashed line = boundary of counted area. Scale bar = 100 µm. 
Figure 3.11 Single label fluorescent staining for O-GlcNAc in the ARC. 
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Bar graph showing the mean (± SEM) number of O-GlcNAc expressing cells in non-pregnant, 
pregnant and lactating rats in the arcuate nucleus. Within each bar the individual scatter plot 
represents the mean number of O-GlcNAc expressing cells for each animal in the group. 
One-way ANOVA revealed no statistical difference between the groups F (2, 18) = 1.75, p = 0.20. 
  
Figure 3.12  O-GlcNAc expressing cells in the ARC. 
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 Co-expression analysis of O-GlcNAc and DFosB in the PVN 
of the rat brain 
Dual label fluorescent immunohistochemistry staining was performed for both O-GlcNAc and 
DFosB expressing cells in the PVN of non-pregnant (n = 8), pregnant (n = 6) and lactating rats 
(n = 5). The mean numbers of O-GlcNAc expressing cells in the PVN were 421 ± 23 in the non-
pregnant group, 347 ± 27 in the pregnant group and 391 ± 50 in the lactating group. Again, 
there was no statistical difference in the mean numbers of O-GlcNAc expressing cells in the 
PVN (F (2, 16) = 1.32, p = 0.29, one-way ANOVA) (Figure 3.14, 3.15).  
The mean numbers of DFosB expressing cells in the PVN were 6.2 ± 0.6 in the non-
pregnant group, 4.8 ± 0.5 in the pregnant group and 6.9 ± 1 in the lactating group. The mean 
numbers of DFosB expressing cells in the PVN were not statistically different between the 
three groups (F (2, 16) = 2.1, p = 0.15, one-way ANOVA) (Figure 3.16). 
The percentage of O-GlcNAc cells co-expressing DFosB was calculated for each group. 
Non- pregnant rats had 1.5 ± 0.09% co-expression, pregnant rats had 1.4 ± 0.09% and lactating 
rats had 1.8 ± 0.3% O-GlcNAc cells co-expressing DFosB. No statistical change was detected in 
the percentage of O-GlcNAc cells co-expressing DFosB (F (2,16) = 2.0, p = 0.16, one-way ANOVA) 
(Figure 3.17). 
I also quantified the percentage of DFosB cells co-expressing O-GlcNAc and the mean 
percentage of co-expression was 85 ± 2% in the non-pregnant group 85 ± 3% in the pregnant 
group and 87 ± 4% in the lactating group. There was no statistical change in the percentage of 
DFosB co-expressing O-GlcNAc between non-pregnant, pregnant or lactating rats (F (2,16) = 0.17 
p = 0.84, one-way ANOVA) (Figure 3.18). 
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DFosB expressing cells          O-GlcNAc expressing cells 
DFosB and O-GlcNAc images overlaid showing co-expressed cells in yellow. 
Representative images of DFosB (green stain) and O-GlcNAc (red stain) using fluorescent 
immunohistochemistry. Images taken in the PVN of a pregnant rat at 40 x objective.  
Scale bar = 50 µm.  
  
Figure 3.13 Double label fluorescent staining. 
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Non-pregnant            Pregnant 
      Lactating 
Representative images showing O-GlcNAc expressing cells (red) and DFosB activated cells 
(green) in the PVN of non-pregnant, pregnant and lactating rats.  
White dashed line = boundary of counted area. Scale bar = 100 µm.  
Figure 3.14 Fluorescent O-GlcNAc and DFosB staining in the PVN. 
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Bar graph showing the mean (± SEM) number of O-GlcNAc expressing cells in non-pregnant, 
regnant and lactating rats in the paraventricular nucleus. Within each bar the individual scatter 
plot represents the mean number of O-GlcNAc expressing cells for each animal in the group. 
One-way ANOVA revealed no statistical difference between the groups F (2, 16) = 1.32, p = 0.29. 
Graph showing the mean (± SEM) number of DFosB expressing cells in non-pregnant, pregnant 
and lactating rats in the paraventricular nucleus. Within each bar the individual scatter plot 
represents the mean number of O-GlcNAc expressing cells for each animal in the group. One-
way ANOVA revealed no statistical difference between the groups F (2, 16) = 2.1, p = 0.15. 
Figure 3.16 DFosB expressing cells in the PVN. 
Figure 3.15 O-GlcNAc expressing cells in the PVN. 
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Graph showing the mean (± SEM) percentage of O-GlcNAc cells co-expressing DFosB in non-
pregnant, pregnant and lactating rats in the paraventricular nucleus. Within each bar the 
individual scatter plot represents the mean percentage of O-GlcNAc cells co-expressing DFosB 
for each animal in the group. One-way ANOVA revealed no statistical difference between the 
groups F (2,16) = 2.0, p = 0.16. 
Graph showing the mean (± SEM) percentage of DFosB cells co-expressing O-GlcNAc in non-
pregnant, pregnant and lactating rats in the paraventricular nucleus. Within each bar the 
individual scatter plot represents the mean percentage of DFosB cells co-expressing O-GlcNAc 
for each animal in the group. One-way ANOVA revealed no statistical difference between the 
groups F (2,16) = 0.17 p = 0.84. 
Figure 3.18 The percentage of O-GlcNAc cells co-expressing DFosB in the PVN. 
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Chapter 4 Discussion 
In the present study I aimed to test the hypothesis that the number of O-GlcNAc expressing 
cells would increase in pregnant rats and return to normal or decrease in lactation. 
Interestingly, the expression of O-GlcNAc was abundant throughout the brain slices of all the 
animals. In contrast to my hypothesis, I discovered no changes in the number of O-GlcNAc 
expressing cells between non-pregnant, pregnant and lactating rats in the VMH, PVN, SON, 
ARC, Pe and AVPV. Furthermore, using double-label immunohistochemistry for O-GlcNAc and 
DFosB, a marker for activation, we found very few chronically activated O-GlcNAc expressing 
cells in the PVN. The number of DFosB cells were also unchanged between non-pregnant, 
pregnant and lactating groups.  
 
 O-GlcNAc expression 
O-GlcNAc immunostaining was carried out on brain sections from non-pregnant, pregnant and 
lactating rats. Representative images (3.1 – 3.18) showed, O-GlcNAc is an abundant protein 
modification throughout the brain. The copious presence of O-GlcNAc in many areas of the 
rodent brain indicates it has many potential roles consistent with the literature (Alfaro et al., 
2012, Hart et al., 2011). Research showing immunohistochemistry for O-GlcNAc throughout 
the brain in pregnant or lactating rats is scarce. In this study I was able to determine that during 
the normal physiological conditions of pregnancy and lactation, O-GlcNAcylation was largely 
unchanged throughout whole nuclei within the hypothalamus compared with the non-
pregnant state.  
As O-GlcNAc is described as a nutrient and stress sensor it was very unexpected to see 
no changes between non-pregnant, pregnant and lactating rats, when there are many 
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metabolic changes occurring. I expected the largest changes in expression to be seen in the 
VMH, ARC and PVN due to their varying functions in metabolic homeostasis and energy 
homeostasis. During pregnancy, adaptations occur in the insulin and leptin signaling pathways 
due to the decreased sensitivity of the brain to insulin and leptin that arises. These adaptations 
are then reversed in lactation when they are no longer needed. Contrary to my hypothesis, 
these adaptations do not appear to be driven by O-GlcNAcylation or as a result of changes in 
O-GlcNAcylation. 
Steady O-GlcNAc expression in the hypothalamus suggests homeostatic mechanisms 
are controlling O-GlcNAcylation levels in physiological states of fluctuating stress and nutrition. 
This is highly possible as we know that the perturbance of O-GlcNAc has been linked to many 
diseases (Ma & Hart, 2013, Zeidan & Hart, 2010, Hart et al., 2011) (Figure 1.2). Developing 
disease from the stress and nutrient fluctuations of pregnancy and lactation would be 
detrimental to the body, serving no beneficial outcomes to the mother and fetus. HyperO-
GlcNAcylation is said to cause insulin resistance and lead to TIIDM, heart failure, metabolic 
syndrome and hypertension (Bond & Hanover, 2013, Hardville & Hart, 2014, Ma & Hart, 2013). 
Whereas, hypoO-GlcNAcylation is linked to many neurological disorders such as Alzheimer’s, 
Parkinson’s disease and Huntington’s disease (Lefebvre et al., 2010, Liu et al.,2004, Liu et al., 
2009, Hart et al., 2011, Hart et al., 2007). The optimal O-GlcNAcylation level has been proposed 
to be within a ‘buffer’ region. This allows for normal fluctuation of O-GlcNAc within 
physiological conditions without any detriment. Chronic nutrient or stress insults could disrupt 
this homeostasis eventually leading to the development of diseases (Yang & Quian, 2017) 
(Figure 4.1). 
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O-GlcNAcylation is normally maintained at an optimal level by OGT and OGA in a buffer region 
of varying nutrient availability and cellular stress. When the cellular stress or nutrient 
availability is chronically increased O-GlcNAcylation increases leading to disease. When the 
nutrient availability is chronically decreased O-GlcNAcylation decreases also leading to 
disease. (Image from Yang & Quian, 2017) 
 
 Mechanism for O-GlcNAcylation homeostasis 
The production of UDP-GlcNAc is partially controlled by the HPB flux, blood glucose levels and 
stress (Figure 1.1) however, the addition of O-GlcNAc onto a protein can be controlled by 
many factors. OGT and OGA are the sole enzymes regulating the O-GlcNAc modification, but 
nonetheless can still be modified themselves. OGT is shown to be regulated by insulin whereby 
the insulin binds to IRS which directly phosphorylates OGT. Insulin can also stimulate indirect 
phosphorylation of a tyrosine residue on OGT (Whelan et al., 2008). Direct or indirect 
phosphorylation of OGT by insulin results in increased enzymatic OGT activity (Whelan et al., 
Figure 4.1 Maintenance of O-GlcNAcylation homeostasis. 
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2008). OGT also contains multiple UDP-GlcNAc binding sites allowing its activity to be 
regulated by the O-GlcNAc modification itself (Kreppel & Hart, 1999). Phosphorylation and O-
GlcNAcylation are said to have extensive cross talk (Hart et al., 2011, Wang et al., 2008) 
allowing for careful manipulation of protein function. The interplay between phosphorylation 
and O-GlcNAcylation of OGT could be regulating O-GlcNAcylation during pregnancy and 
lactation. This interaction could also be where the mechanism fails in chronic disease. 
Hyperphosphorylation or hyperO-GlcNAcylation of OGT could increase the enzyme activity 
resulting in excess O-GlcNAcylation of target proteins.  
 
 OGT as a nutrient sensor 
The ARC is a key sight for appetite regulation where orexigenic and anorexigenic neurons 
reside and send afferents to the PVN (Figure 1.3) (Bai et al., 1985, Sternson et al., 2005). Within 
the ARC these neurons respond to many hormone signals, including leptin and insulin for 
satiety signals and information to stop eating (Cowley et al.,2001). Perturbations in the 
appetite regulating signaling pathways within the brain can lead to overeating and obesity. 
Increases in O-GlcNAcylation have been reported in obese and hyperglycemic states (Hart et 
al., 2011, Ma & Hart 2013, Zeidan & Hart, 2010). During pregnancy insulin and leptin 
resistance leads to an increase in food intake and weight gain and in some cases 
hyperglycemia and gestational diabetes. We expected to see an increase in O-GlcNAc within 
these appetite regulating centres of the brain during pregnancy. The present studies results 
however, showed no change in O-GlcNAc expression within these areas.  
Using a different approach, studies done by Lagerlöf et al (2016) and Dai et al (2018) 
have shown neuronal knockout of OGT in alpha-Ca2+/calmodulin-dependent protein kinase II 
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(aCAMKII) cells in adult mice causes reversible overeating, obesity and insulin resistance. The 
study’s suggest OGT is a nutrient sensor with a crucial role in generating the satiety response. 
This is intriguing as a knockout of OGT suggests minimal neural O-GlcNAcylation is occurring 
whereas, in studies of hyperglycemia and diabetes hyperO-GlcNAcylation occurs. In the OGT 
knockout mouse model, there is less O-GlcNAcylation occurring in aCAMKII cells and the brain 
starts signalling for more nutrient intake leading to increased food intake. The lack of an O-
GlcNAcylation response to increased food intake, can further lead to insulin resistance. The 
OGT knockout mice are overeating providing their bodies with adequate nutrition which is 
simply not sensed in the brain.  
In an OGT knockout O-GlcNAcylation is minimal, leaving the possibility of neurological 
defects, as we know hypoO-GlcNAcylation can cause these (Lefebvre et al., 2010, Liu et 
al.,2004, Liu et al., 2009, Hart et al., 2011). This approach questions my hypothesis and 
suggests in pregnancy overeating could be driven by decreased OGT activity and therefore we 
should possibly be expecting lower levels of O-GlcNAc. Our results, however, have not shown 
a lower level of O-GlcNAcylation in any analysed nuclei.  
  
 Insulin resistance and O-GlcNAcylation  
The interaction between O-GlcNAcylation and insulin resistance seems to be a key driver 
towards chronic disease. Insulin resistance is correlated with TIIDM, heart failure, 
hypertension, decreased baroreflex function and pre-eclampsia. HyperO-GlcNAcylation has 
previously been shown to play a role in the development of insulin resistance by the addition 
of O-GlcNAc to IRS-1, IRS-2 and phosphoinositide-dependent protein kinase-1 (PDK1). The O-
GlcNAcylation of these proteins leads to the down regulation of AKT activity decreasing insulin 
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signaling (Whelan et al., 2010). As discussed above the knockout of OGT and therefore hypoO-
GlcNAcylation also leads to insulin resistance. In a normal pregnancy we know there is some 
insulin resistance however this does not lead to disease. In a pregnancy with gestational 
diabetes or pre-eclampsia, insulin resistance could be driven by the increase or decrease in 
OGT activity. A future experiment determining the expression of OGT in both pregnant rats 
and a rat model of gestational diabetes could determine if any changes are occurring.  
 
 Chronic activation in O-GlcNAcylated cells 
DFosB is a stable transcription factor that increases in response to a repeated neural stimulus 
It is normally used in addiction studies and is known to be a good indicator of chronic neural 
activation. I used DFosB as a marker to be able to determine if cells within the PVN expressing 
O-GlcNAc are chronically activated by the glucose stimulus. l carried out immunostaining for 
co-expressed O-GlcNAc and DFosB in the PVN. The PVN was analysed as it is where AgRP/NPY 
neurons and POMC neurons project to, regulating food intake, insulin sensitivity and energy 
expenditure (Figure 1.3). In the previous result, using chromogen staining, the number of O-
GlcNAc expressing cells was unchanged (Figure 3.4). However, it was still possible that the O-
GlcNAcylated cells were chronically activated during pregnancy. Decreased insulin sensitivity 
and increased food intake during pregnancy could lead to changes in chronic activation of 
certain cells within the PVN. My results revealed the level of chronic activation in O-GlcNAc 
expressing cells, was ~ 1.5% in the PVN across all three groups (Figure 3.15). This is intriguingly 
low and again suggests that during a normal pregnancy and subsequent lactation, O-
GlcNAcylation is well regulated, not allowing chronic activation of certain proteins or neural 
pathways. As no change was seen in the number of O-GlcNAc expressing cells or the number 
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of DFosB expressing cells, the double-label was not continued in other regions of the 
hypothalamus.  
It is well known that O-GlcNAc cycling is very dynamic with a fast turnover rate (Bond & 
Hanover, 2013). O-GlcNAc also has multiple binding sites on many proteins and therefore an 
increase in activation of DFosB may not occur as the same targets may not be repeatedly 
stimulated. Within the PVN, parvocellular neurons that act on SNA have decreased activity 
during pregnancy (Deng & Kaufman, 1995), suggesting chronic activation from O-GlcNAc may 
not occur in these cells. 
Pregnancy and lactation are however physiological conditions and could be within the 
buffer region of O-GlcNAc homeostasis. Again, using a gestational diabetes or pre-eclampsia 
model could reveal whether O-GlcNAc does become chronically activated in pathological 
conditions.  
 
 Limitations and future directions 
4.6.1 First limitation of this study 
The main limitation of immunohistochemistry is that it does not provide any quantification of 
the change in protein expression. We can see that there is O-GlcNAc expression in certain cells 
however the changes in protein expression remains unknown during pregnancy and lactation. 
In the future a western blot could be used to determine the changes in O-GlcNAc protein 
expression within the tissue or changes in the amount of protein O-GlcNAcylation. To do this 
however O-GlcNAcylated proteins need to be identified. This process has been expensive and 
complicated in the past but new methods are making the experiments more accessible (Ma 
et al., 2019). Of the thousands of proteins that are known to be O-GlcNAcylated the ones to 
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look at within the hypothalamus for changes during pregnancy and lactation are unknown, as 
there may be several proteins and identifying each of them could prove time consuming. 
Starting with the insulin signaling pathway, specifically IRS-1 would initiate more of an 
understanding in the relationship between insulin resistance and O-GlcNAc during pregnancy.  
Determining the ratio of expression between the OGT and OGA enzymes using 
Quantitative Polymerase Chain Reaction (qPCR) could also be a preliminary experiment done 
to determine if the addition or removal of O-GlcNAc is changing during pregnancy and 
lactation. Future experiments could also include using gestational diabetes rat models to 
determine if there are any pathological changes as well as physiological changes in OGT or 
OGA enzyme activity. 
Using western blotting, phosphorylation and O-GlcNAcylation of OGT could be 
investigated. Western blots could be used to determine whether hyperphosphorylation or 
hyperO-GlcNAcylation of OGT is occurring, resulting in changes to OGT’s enzymatic activity in 
a normal pregnancy or in a gestational diabetes rodent model.  
 
4.6.2 Second limitation of this study 
A second limitation of this study was the assumption from previous research (Newbern & 
Freemark, 2011, Burnol et al., 1983) that blood glucose levels would be higher in the pregnant 
rats and lower in lactating rats. When the tissues were collected blood glucose measurements 
of the rats were not taken and no record existed of when the animals last ate. The time of the 
last meal could account for the outliers in my results as O-GlcNAc is a nutrient sensor. If an 
animal had just eaten a meal it is more likely to have higher O-GlcNAc expression, therefore 
confounding the results. My hypothesis that O-GlcNAc expression increased in pregnancy was 
partially based on an increase in glucose levels. However, as glucose levels were not 
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measured, we cannot determine whether they were any different between the non-pregnant, 
pregnant and lactating rats. In the future blood glucose measurements should be taken at the 
time of euthanasia.  
It is also known that blood glucose levels oscillate in a circadian rhythm in ad libitim 
fed, pregnant and 18 hour fasted rats (Ruiter et al., 2003). To fast pregnant and lactating 
animals for more than 18 hours would be extreme, so instead, removing the food at lights on, 
on the day of euthanasia as well as euthanising at similar times of the day could allow for more 
consistent blood glucose levels within each group.  
All of our pregnant rats were euthanised on the last day of pregnancy (day 21), having 
a group euthanised on day 15 of pregnancy may show different results as this is when they 
start to gain the most weight (Hain, 1932) and potentially when the appetite regulating 
centres have the most change.  
 
4.6.3 Third limitation of this study  
A third limitation to this study is that I did not separate the different populations of cells in 
heterogenous nuclei. No change was seen in O-GlcNAc expressing cells between non-
pregnant, pregnant and lactating rats across whole nuclei (ARC, VMH, PVN, SON, Pe, AVPV) 
however, within these nuclei are different subpopulations of cells with varying functions. It 
could be possible that subpopulations of cells expressing O-GlcNAc in each nucleus could 
change at varying degrees and we cannot analyse this when immunostaining the whole 
nucleus without double-labelling for specific cell populations.  
Zachara et al (2004) showed OGT and O-GlcNAc increased in mammalian cells in vitro 
with increases in varying stressors. OGT and O-GlcNAc are also known to increase with 
nutrient availability and increased UDP-GlcNAc levels (Wells et al., 2001) which would suggest 
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increased O-GlcNAc levels in pregnancy. In contrast Ruan et al (2014) found that AgRP/NPY 
neurons in the arcuate nucleus have increased OGT and O-GlcNAc levels when cells were 
nutrient deprived after 24hrs of fasting and Taylor et al (2008) showed in vitro that glucose 
deprivation upregulates O-GlcNAc in a possible energy conserving mechanism. This suggests 
that individual cell populations respond differently to O-GlcNAc in varying nutrient availability. 
The subpopulations within a nucleus could show opposite increases or decreases in O-GlcNAc 
during pregnancy which was not seen when analyzing a whole nucleus.  
Within the PVN there are many populations of neurons with varying functions that may 
be differently O-GlcNAcylated. In our single label O-GlcNAc immunohistochemistry it is 
possible to identify magnocellular neurons from parvocellular neurons. Magnocellular cells 
are larger more lateral and contain vasopressin and oxytocin neurons whereas, parvocellular 
cells are smaller more medial and include thyrotropin-releasing hormone (TRH), 
corticotrophin-releasing hormone (CRH), sympathoexcitatory neurons from the brain stem 
and others. Using a double label immunofluorescence stain for O-GlcNAc expressing cells and 
dopamine beta-hydroxylase (DHB) expressing cells (expressed in sympathoexcitatory neurons 
from the brainstem involved in SNA) could separate some of these populations. With this co-
label, cells that express both DHB and O-GlcNAc can be counted, magnocellular cells can be 
counted and the parvocellular cells without DHB (TRH, CRH) can be counted. TRH and CRH can 
also be separately double-labelled with O-GlcNAc. Individually counting smaller populations 
of neurons within larger nuclei could result in different changes in O-GlcNAc expression across 
pregnant and lactating rats that weren’t seen at the whole nuclei level.  
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 Conclusion 
Throughout the many metabolic and hemodynamic adaptations that occur during a normal 
pregnancy, my results suggest none are driven by changes in O-GlcNAcylation. Within the 
fluctuations of nutrients during a normal pregnancy and lactation there may be a mechanism 
controlling O-GlcNAc homeostasis. A failure of this mechanism could lead to the development 
of GDM or pre-eclampsia.   
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